- Trial phase
- Approved
- Time to market
- Already approved and commercially available (oral since 2018, IV since 2022).
- Why 4/10
- TPOXX is already FDA-approved and commercially marketed with no pending PDUFA or pivotal readout in the next ~12 months; the next hard catalyst is Q3 2026 earnings (Nov 5, 2026), which is a quarterly commercial update, not a binary drug-approval event. The planned FDA submission for PEP is targeted for H1 2027, over 6 months away. Per the rubric, an approved drug with no imminent regulatory binary scores 3-5.
The next hard catalyst is Q3 2026 earnings on November 5, 2026, which will show whether TPOXX deliveries continued and whether management has secured a new multi-year BARDA procurement contract. Without a new contract, the revenue cliff from the nearly-exhausted 19C contract is the dominant risk. The longer-term catalyst is the planned FDA submission for post-exposure prophylaxis in H1 2027, but that is over six months away and not yet a binary event.
Price Chart
Executive Summary
TPOXX (tecovirimat) is the only FDA-approved drug specifically indicated for treating smallpox, developed by SIGA Technologies (NASDAQ: SIGA). Approved orally in 2018 and intravenously in 2022, it is sold almost exclusively to governments for biodefense stockpiling, with the U.S. government (BARDA) as the dominant customer under a contract valued at up to $630M. The stock has fallen ~60% from its 52-week high as the BARDA contract nears exhaustion (~86% exercised), two mpox trials failed primary endpoints, and the EMA withdrew the mpox indication in March 2026. Q2 2026 revenue fell 49% YoY to $41M. The company is pursuing label expansion into post-exposure prophylaxis (FDA submission targeted H1 2027) and a pediatric formulation, but faces a revenue cliff without a new multi-year procurement contract.
How It Works
TPOXX is an antiviral that blocks the VP37 envelope-wrapping protein of orthopoxviruses (the family that includes smallpox, monkeypox/mpox, and cowpox). By inhibiting this protein, the drug prevents the virus from leaving infected cells and spreading to new cells in the body. It is taken as oral capsules or given intravenously for patients who cannot swallow.
Trial Status
TPOXX is FDA-approved for smallpox treatment in adults and pediatric patients weighing at least 13 kg (oral) or 3 kg (IV). Two Phase 3 mpox trials (PALM 007 and STOMP) failed to meet primary endpoints. The company is developing a pediatric oral suspension (Phase 1) and pursuing post-exposure prophylaxis (PEP) with an FDA submission targeted for H1 2027.
The Two-Sided Case
Upcoming Catalysts
- Q3 2026 earnings report on November 5, 2026, which will reveal TPOXX delivery volumes and any update on new BARDA procurement contract
- Potential new multi-year U.S. government procurement contract to replace the expiring 19C BARDA contract
- FDA submission for post-exposure prophylaxis (PEP) targeted for first half of 2027
- Phase 1 results for pediatric oral suspension formulation
Source Filing
The SecBot filing or press-release report that triggered this drug report:
SIGA Technologies Inc. Press Release SIGA ·Originating report